文摘
摘要目的:探讨MS患者的皮层和丘脑显微结构的异常显示进步的距离CSF及其临床意义。
背景:CSF-in梯度在皮层和丘脑损害已经建议在多发性硬化症(MS),可能由于CSF-mediated病理过程。然而,这种模式的并发损伤尚未探索体内和在大脑皮层和丘脑。
设计/方法:大脑3 t-mri序列从52获得医学患者(33复发缓和(RR), 19进步[P]), 56健康对照组(HC)。从3 dt1-weighted序列,皮质层采样在25% -50% -75%深度从白质(WM)皮质接口(Freesurfer)和丘脑的同心乐队从ventricular-thalamus 1-2-3-voxels接口(内部实现方法)。群体间的比较(地铁)磁化传递率值,在皮层和丘脑的层和髓鞘形成指数与临床的相关性和结构措施评估使用线性混合模型和斯皮尔曼相关系数。
结果:与HC相比,名RRMS和经前综合症患者显示显著降低地铁值在最表面的皮质层(名RRMS =−1.23%, p = 0.006,经前综合症=−1.70%,p = 0.002),没有差异。HC相比,名RRMS和经前综合症患者显示显著降低地铁值带离心室(名RRMS =−1.63%, p = 0.015,经前综合症=−3.62%,p < 0.001)。PMS显示也显著降低地铁在ventricle-closest乐队名RRMS相比(p = 0.022)和第二乐队相比,HC (−1.07%, p = 0.048)。降低地铁的价值观CSF-closest皮层和丘脑的层长有显著相关性疾病持续时间、高扩展残疾状态量表(eds)评分,更高的WM病变体积(r从0.45−−0.35,p≤0.011),低规范化大脑、丘脑和大脑皮层卷(r从0.42到0.56,p≤0.002)。
结论:女士,临床相关CSF-in梯度损伤可以检测到3 t的皮层和丘脑,更大量的在丘脑和经前综合症。
披露:鲁宾博士没有披露。伊丽莎白帕加尼没有披露。Loredana Storelli没有披露。亚历山德罗代表我没有披露。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在百时美施贵宝公司的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在赛诺菲Genzyme的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在诺华的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在罗氏的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在默克的演讲人。莫妮卡Margoni接到MAGNIMS研究支持。 Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva. The institution of Maria Assunta Rocca has received research support from Italian Ministry of Health, MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
